Aurinia Pharmaceuticals to Present at Upcoming September Investor ConferencesBusiness Wire • 09/15/21
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/10/21
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock OptionsZacks Investment Research • 08/18/21
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related DiseasesBusiness Wire • 08/17/21
Aurinia Pharmaceuticals Inc. (AUPH) CEO John Leonard on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/06/21
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational HighlightsBusiness Wire • 08/05/21
Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021Business Wire • 07/26/21
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)Business Wire • 06/25/21
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of DirectorsBusiness Wire • 06/14/21
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 CongressBusiness Wire • 06/07/21
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferenceBusiness Wire • 05/27/21